Cystatin C as a predictor of mortality and cardiovascular events in a population with chronic kidney disease

Ana Vigil, Emilia Condés, Luis Vigil, Paloma Gallar, Aniana Oliet, Olimpia Ortega, Isabel Rodriguez, Milagros Ortiz, Juan Carlos Herrero, Carmen Mon, Gabriela Cobo, Juana Jimenez, Ana Vigil, Emilia Condés, Luis Vigil, Paloma Gallar, Aniana Oliet, Olimpia Ortega, Isabel Rodriguez, Milagros Ortiz, Juan Carlos Herrero, Carmen Mon, Gabriela Cobo, Juana Jimenez

Abstract

Background. We examine whether cystatin C, a surrogate marker of renal function, could identify patients with chronic kidney disease (CKD) with an increased risk of renal disease progression, death, or cardiovascular events. Methods. Data were obtained for 180 patients, with a diagnosis of chronic renal failure based on serum creatinine estimated glomerular filtration rate (eGFRcreat) <90 mL/min/1.73 m(2). This population was grouped in tertiles according to cystatin C and creatinine values at baseline. Cardiovascular events and overall mortality were estimated for each tertile. Predictors of overall mortality and for the development of renal disease progression were analyzed. Results. The median age was 75 years (interquartile range 69-82) and the median eGFRcreat 38 mL/min m(2) (interquartile range 33-49). Overall mortality was lower on the first and on the second tertiles of cystatin C than on the third one (HR = 0.060; 95% CI: 0.008-0.447 and HR = 0.094; 95% CI: 0.022-0.406, resp.). Deaths related to the creatinine tertiles followed the same pattern, but differences were not as large. Cardiovascular mortality was lower on the second than on the third cystatin C tertile (HR = 0.198; 95% CI: 0.040-0.987), but it did not show differences on the first and the second creatinine tertiles compared with the third one (HR = 0.126; 95% CI: 0.013-1.265 and HR = 0.403; 95% CI: 0.093-1.740). The only independent predictors of mortality during followup were baseline cystatin C (OR = 0.100; 95% CI: 0.021-0.463) and baseline uric acid (OR = 1.377; 95% CI: 1.070-1.773). Conclusion. Cystatin C may be an alternative to creatinine for detecting a high risk of death and cardiovascular events in a population with CKD.

Figures

Figure 1
Figure 1
Distribution of patients according to estimated GFR defined by cystatin C and creatinine tertiles. CKD: chronic kidney disease; eGFRcreat and eGFRcyst: estimated glomerular filtration rate according to creatinine and cystatin C; T1: tertile 1; T2: tertile 2; T3: tertile 3.
Figure 2
Figure 2
Survival and tertiles of cystatin C.
Figure 3
Figure 3
Survival and baseline uric acid levels.

References

    1. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. American Journal of Nephrology. 2007;27(2):197–205.
    1. Eriksen BO, Mathisen UD, Melsom T, et al. Cystatin C is not a better estimator of GFR than plasma creatinine in the general population. Kidney International. 2010;78(12):1305–1311.
    1. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. Journal of the American Society of Nephrology. 2011;22(1):147–155.
    1. Vigil L, Lopez M, Condés E, et al. Cystatin C is associated with the metabolic syndrome and other cardiovascular risk factors in a hypertensive population. Journal of the American Society of Hypertension. 2009;3(3):201–209.
    1. Magnusson M, Hedblad B, Engström G, Persson M, Nilsson P, Melander O. High levels of cystatin C predict the metabolic syndrome: the prospective Malmö Diet and Cancer study. Journal of Internal Medicine. 2013;274(2):192–199.
    1. Balta S, Demirkol S, Ay SA, Cakar M, Sarlak H, Celik T. Serum cystatin-C levels correlate with endothelial dysfunction in patients with the metabolic syndrome. Journal of Internal Medicine. 2013;274(2):200–201.
    1. Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: an emerging biomarker in cardiovascular disease. Current Topics in Medicinal Chemistry. 2013;13(2):164–179.
    1. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. American Journal of Kidney Diseases. 2008;51(3):395–406.
    1. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine. 2009;150(9):604–612.
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine. 2004;164(6):659–663.
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine. 2004;351(13):1296–1370.
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002;39(2, supplement 1):S1–S266.
    1. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Annals of Internal Medicine. 2006;145(4):237–246.
    1. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health study. Clinical Chemistry. 1995;41(2):264–270.
    1. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health study: design and rationale. Annals of Epidemiology. 1991;1(3):263–276.
    1. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. Journal of the American Medical Association. 2011;305(15):1545–1552.
    1. Feig DI, Kang D-H, Johnson RJ. Medical progress: uric acid and cardiovascular risk. The New England Journal of Medicine. 2008;359(17):1811–1821.
    1. Nakagawa T, Kang D-H, Feig D, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney International. 2006;69(10):1722–1725.
    1. Kim YS, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care and Research. 2010;62(2):170–180.
    1. Seo YK, Guevara JP, Kyoung MK, Hyon KC, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Care and Research. 2009;61(7):885–892.
    1. Gagliardi ACM, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis. 2009;202(1):11–17.
    1. Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. American Journal of Kidney Diseases. 2006;48(5):761–771.
    1. Liu W-C, Hung C-C, Chen S-C, et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clinical Journal of the American Society of Nephrology. 2012;7(4):541–548.
    1. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. American Journal of Kidney Diseases. 2009;53(5):796–803.
    1. Krolewski AS, Warram JH, Forsblom C, Smiles AM, Thorn L, Skupien J, et al. Serum concentration of cystatin C and risk of end-stage renal disease in diabetes. Diabetes Care. 2012;35(11):2311–2316.
    1. Fox CS, Gona P, Larson MG, et al. A multi-marker approach to predict incident CKD and microalbuminuria. Journal of the American Society of Nephrology. 2010;21(12):2143–2149.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다